SEARCH

SEARCH BY CITATION

References

  • 1
    Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 2
    Haura EB,Turkson J,Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract 2005; 2: 31524.
  • 3
    Orlowski RZ,Baldwin ASJr. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002; 8: 3859.
  • 4
    Ryan KM,Ernst MK,Rice NR,Vousden KH. Role of NF-κB in p53-mediated programmed cell death. Nature 2000; 404: 8927.
  • 5
    Koch W,Sidransky D. Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma. Semin Radiat Oncol 2004; 14: 1308.
  • 6
    Allen CT,Ricker JL,Chen Z,Van Waes C. Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 95971.
  • 7
    Leeman RJ,Lui VW,Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006; 6: 23141.
  • 8
    Song JI,Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19: 248995.
  • 9
    Ondrey FG,Dong G,Sunwoo J,Chen Z,Wolf JS,Crowl-Bancroft CV,Mukaida N,Van Waes C. Constitutive activation of transcription factors NF-(κ)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26: 11929.
  • 10
    Duffey DC,Chen Z,Dong G,Ondrey FG,Wolf JS,Brown K,Siebenlist U,Van Waes C. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 346874.
  • 11
    Duffey DC,Crowl-Bancroft CV,Chen Z,Ondrey FG,Nejad-Sattari M,Dong G,Van Waes C. Inhibition of transcription factor nuclear factor-κB by a mutant inhibitor-κBα attenuates resistance of human head and neck squamous cell carcinoma to TNF-α caspase-mediated cell death. Br J Cancer 2000; 83: 136774.
  • 12
    Van Waes C,Chang AA,Lebowitz PF,Druzgal CH,Chen Z,Elsayed YA,Sunwoo JB,Rudy SF,Morris JC,Mitchell JB,Camphausen K,Gius D, et al. Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63: 140012.
  • 13
    Zhang PL,Pellitteri PK,Law A,Gilroy PA,Wood GC,Kennedy TL,Blasick TM,Lun M,Schuerch CIII,Brown RE. Overexpression of phosphorylated nuclear factor-κB in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 2005; 18: 92432.
  • 14
    Bancroft CC,Chen Z,Yeh J,Sunwoo JB,Yeh NT,Jackson S,Jackson C,Van Waes C. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99: 53848.
  • 15
    Wolf JS,Chen Z,Dong G,Sunwoo JB,Bancroft CC,Capo DE,Yeh NT,Mukaida N,Van Waes C. IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001; 7: 181220.
  • 16
    Hong SH,Ondrey FG,Avis IM,Chen Z,Loukinova E,Cavanaugh PFJr,Van Waes C,Mulshine JL. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 2000; 14: 1499507.
  • 17
    Lee TL,Yeh J,Van Waes C,Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006; 5: 819.
  • 18
    Pomerantz RG,Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 2003; 5: 1406.
  • 19
    Squarize CH,Castilho RM,Sriuranpong V,Pinto DSJr,Gutkind JS. Molecular cross-talk between the NFκB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006; 8: 73346.
  • 20
    Ren Q,Kari C,Quadros MR,Burd R,McCue P,Dicker AP,Rodeck U. Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor κB signaling. Cancer Res 2006; 66: 520915.
  • 21
    Bradford CR,Wolf GT,Carey TE,Zhu S,Beals TF,Truelson JM,McClatchey KD,Fisher SG. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999; 121: 5348.
  • 22
    Bradford CR,Zhu S,Ogawa H,Ogawa T,Ubell M,Narayan A,Johnson G,Wolf GT,Fisher SG,Carey TE. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003; 25: 65461.
  • 23
    Bradford CR,Zhu S,Wolf GT,Poore J,Fisher SG,Beals T,McClatchey KD,Carey TE. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995; 113: 40812.
  • 24
    Cory S,Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005; 8: 56.
  • 25
    Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000; 19: 662731.
  • 26
    el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 34557.
  • 27
    Harper JW,Adami GR,Wei N,Keyomarsi K,Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 80516.
  • 28
    Miyashita T,Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 2939.
  • 29
    Dong QG,Sclabas GM,Fujioka S,Schmidt C,Peng B,Wu T,Tsao MS,Evans DB,Abbruzzese JL,McDonnell TJ,Chiao PJ. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 2002; 21: 651019.
  • 30
    Duan J,Friedman J,Nottingham L,Chen Z,Ara G,Van Waes C. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 3750.
  • 31
    Grad JM,Zeng XR,Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000; 12: 5439.
  • 32
    Sevilla L,Zaldumbide A,Pognonec P,Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFκB, STAT and AP1 transcription factor families. Histol Histopathol 2001; 16: 595601.
  • 33
    Tsukahara T,Kannagi M,Ohashi T,Kato H,Arai M,Nunez G,Iwanaga Y,Yamamoto N,Ohtani K,Nakamura M,Fujii M. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-κB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999; 73: 79817.
  • 34
    Xi S,Gooding WE,Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005; 24: 9709.
  • 35
    Frederick MJ,Holton PR,Hudson M,Wang M,Clayman GL. Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death. Clin Cancer Res 1999; 5: 3619.
  • 36
    Grandis JR,Drenning SD,Zeng Q,Watkins SC,Melhem MF,Endo S,Johnson DE,Huang L,He Y,Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 422732.
  • 37
    Krecicki T,Fraczek M,Kozlak J,Zatonski T,Jelen M,Dus D. Bcl-Xl protein expression in laryngeal squamous cell carcinoma. Clin Otolaryngol Allied Sci 2004; 29: 558.
  • 38
    Pena JC,Thompson CB,Recant W,Vokes EE,Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999; 85: 16470.
  • 39
    Bauer JA,Trask DK,Kumar B,Los G,Castro J,Lee JS,Chen J,Wang S,Bradford CR,Carey TE. Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 2005; 4: 1096104.
  • 40
    Krause CJ,Carey TE,Ott RW,Hurbis C,McClatchey KD,Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981; 107: 70310.
  • 41
    Yan B,Yang X,Lee TL,Friedman J,Tang J,Van Waes C,Chen Z. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007; 8: R78.
  • 42
    Catlett-Falcone R,Landowski TH,Oshiro MM,Turkson J,Levitzki A,Savino R,Ciliberto G,Moscinski L,Fernandez-Luna JL,Nunez G,Dalton WS,Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 10515.
  • 43
    Chang AA,Van Waes C. Nuclear factor-κB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol 2005; 62: 92102.
  • 44
    Tang DG,Li L,Chopra DP,Porter AT. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998; 58: 346679.
  • 45
    Zhang L,Yu J,Park BH,Kinzler KW,Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290: 98992.
  • 46
    Shimizu S,Narita M,Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 4837.
  • 47
    Leong PL,Andrews GA,Johnson DE,Dyer KF,Xi S,Mai JC,Robbins PD,Gadiparthi S,Burke NA,Watkins SF,Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100: 413843.
  • 48
    Wang J,Ouyang W,Li J,Wei L,Ma Q,Zhang Z,Tong Q,He J,Huang C. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor κB induced by UV radiation. Cancer Res 2005; 65: 660111.
  • 49
    Gray MJ,Zhang J,Ellis LM,Semenza GL,Evans DB,Watowich SS,Gallick GE. HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24: 311020.
  • 50
    Niu G,Wright KL,Ma Y,Wright GM,Huang M,Irby R,Briggs J,Karras J,Cress WD,Pardoll D,Jove R,Chen J, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005; 25: 743240.
  • 51
    Rocha S,Garrett MD,Campbell KJ,Schumm K,Perkins ND. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 2005; 24: 115769.
  • 52
    Rocha S,Martin AM,Meek DW,Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol Cell Biol 2003; 23: 471327.
  • 53
    Wang R,Cherukuri P,Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 2005; 280: 1152834.
  • 54
    Webster GA,Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 1999; 19: 348595.
  • 55
    Rocco JW,Leong CO,Kuperwasser N,DeYoung MP,Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 4556.
  • 56
    Friedman J,Nottingham L,Duggal P,Pernas FG,Yan B,Yang XP,Chen Z,Van Waes C. Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer. Clin Cancer Res 2007 13: 656878.
  • 57
    Gonzalez MV,Pello MF,Lopez-Larrea C,Suarez C,Menendez MJ,Coto E. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1995; 1: 10439.
  • 58
    Kropveld A,van Mansfeld AD,Nabben N,Hordijk GJ,Slootweg PJ. Discordance of p53 status in matched primary tumours and metastases in head and neck squamous cell carcinoma patients. Eur J Cancer B Oral Oncol 1996; 32B: 38893.
  • 59
    Lee TL,Yang XP,Yan B,Friedman J,Duggal P,Bagain L,Dong G,Yeh NT,Wang J,Zhou J,Elkahloun A,Van Waes C,Chen Z. A novel nuclear factor-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007; 13: 568091.
  • 60
    Joyce D,Albanese C,Steer J,Fu M,Bouzahzah B,Pestell RG. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001; 12: 7390.
  • 61
    Mistry P,Deacon K,Mistry S,Blank J,Patel R. NF-κB promotes survival during mitotic cell cycle arrest. J Biol Chem 2004; 279: 148290.
  • 62
    Metge B,Ofori-Acquah S,Stevens T,Balczon R. Stat3 activity is required for centrosome duplication in chinese hamster ovary cells. J Biol Chem 2004; 279: 418016.
  • 63
    Blanke CD. Gefitinib in colorectal cancer: if wishes were horses. J Clin Oncol 2005; 23: 54469.
  • 64
    Zavrski I,Jakob C,Schmid P,Krebbel H,Kaiser M,Fleissner C,Rosche M,Possinger K,Sezer O. Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005; 16: 47581.
  • 65
    Khuri FR,Nemunaitis J,Ganly I,Arseneau J,Tannock IF,Romel L,Gore M,Ironside J,MacDougall RH,Heise C,Randlev B,Gillenwater AM, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 87985.
  • 66
    Rogulski KR,Freytag SO,Zhang K,Gilbert JD,Paielli DL,Kim JH,Heise CC,Kirn DH. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 11936.